# 1. Financial Performance ## A. Key Figures * **Proforma Revenue:** ₹2,390 Cr (+13% YoY) · **Operating EBITDA:** ₹550 Cr (+17%) · **Normalised PAT:** ₹258 Cr (+22%) * **Consolidated Revenue (Q2 FY26):** ₹1,197 Cr (+10% YoY) · **Underlying Growth:** +13% adj. * Kerala Cluster Revenue: ₹620 Cr (+11%) · EBITDA: ₹166 Cr (+19%) · Margin: 26.8% (from 25.0% prior) * **H1 India Revenue:** ₹2,275 Cr (+9%) · **EBITDA:** ₹478 Cr (+17%) * **Normalised PAT (Q2 FY26):** ₹110 Cr (+14% YoY) · **H1 PAT (Post NCI):** ₹200 Cr (+17%) * ROCE: 20.9% H1 FY26 (up 290 bps) * **Cash & Equivalents:** ₹1,276 Cr · **Gross Debt:** ₹639 Cr ## B. Revenue Growth * **Sustained Momentum:** 20 consecutive quarters of YoY revenue growth reflect resilient demand and effective scaling across clusters. * **Volume & Pricing Power:** Revenue expansion driven by **strong double-digit growth** in patient volumes and ARPP, particularly in IP services. * **Cluster Divergence:** Emerging units delivered **85% YoY revenue growth**, significantly outpacing mature units (5%), highlighting successful ramp-up and market penetration. * **Strategic Recovery:** Kerala market rebounded strongly with **double-digit revenue and EBITDA growth**, supported by richer specialty mix and operational stabilization. * **CGHS Tailwind:** Revised CGHS contracts adding **~₹2 Cr/month in revenue**, with **75–80% flowing to EBITDA**, providing a durable margin uplift. ## C. EBITDA Margin * **Margin Expansion Achieved:** Operating EBITDA margin rose **200 bps QoQ to 22%**, driven by Kerala recovery, cost discipline, and improved clinical efficiency. * **Operational Leverage:** Despite softer seasonal trends and lower high-margin disease volumes, margins expanded **53 bps YoY** on cost optimization and procurement synergies. * **Centralized Efficiencies:** **~100 bps reduction in overhead costs** from centralized procurement and renewable energy adoption, exceeding initial synergy targets. * **F&B In-Sourcing Impact:** Margin gains supported by insourcing of food and beverage operations, improving patient experience and **directly benefiting the P&L**. * **Labs & Specialty Growth:** Labs margin improved to **8%**, while **Oncology grew 26% YoY**, contributing to favorable mix despite **material cost headwinds (~80 bps)**. ## D. Profitability Trends * **Earnings Resilience:** Profit growth outpaced revenue despite adverse case mix and lower vector-borne disease incidence, underscoring structural improvements. * **Capital Efficiency:** ROCE expanded over **290 bps to 9%**, reflecting stronger returns and disciplined capital allocation post-merger. * **Long-Term Trajectory:** 5-year **38% EBITDA CAGR** versus **20% revenue CAGR** highlights sustained operating leverage and margin accretion. * **Medicine Margin Pressure:** Pharmacy segment saw **~50% margin compression**, partially offsetting revenue decline impact on overall profitability. ## E. Balance Sheet * **Robust Liquidity:** Strong cash position of **₹1,276 Cr** and moderate leverage (gross debt: ₹639 Cr) provide flexibility for growth and deleveraging. --- # 2. Patient Volume & ARPP ## A. Key Figures * **Inpatient Volume:** **12% QoQ growth** in Q2 FY26 · **67% QoQ / 49% YoY growth** in MVT (Kerala) * **Total Patient Volume:** **15% QoQ growth** (Q2 FY26), driven by outpatient and inpatient momentum * **Occupancy:** Improved to **69%** from 64% in prior quarter (Kerala) * **ARPP (IP):** **10% YoY growth** overall · **5% YoY growth** in Kerala · **QCIL ARPOB: ~₹44,000** * Operating EBITDA Margin (Kerala): Expanded to 26.8% from 22.3% in Q4 FY25 * **MVT Growth:** **60% QoQ / 26% YoY** nationwide · **26% YoY footfall increase** ## B. Inpatient Volume & Utilization * **Strong Recovery in Kerala:** Robust sequential and year-on-year growth in inpatient volumes and MVT, with occupancy rebounding to near 70%, driven by higher elective and high-acuity admissions. * **New Facility Ramp-Up:** Kasaragod hospital launched successfully with **daily OPD footfall >150** and steady inpatient build, supported by rapid clinical staffing. * **Regional Divergence:** Nationwide, internal medicine and related specialties saw de-growth, with **Bangalore impacted by 26%** due to seasonality, offsetting milder declines in Kerala. * **Operational Efficiency:** **Aster’s ALOS improved 6% YoY**, now at **2 days**, reflecting protocol-driven care; further reductions expected to enhance capacity utilization. ## C. ARPP (IP) Trends & Revenue Quality * **Pricing and Mix Discipline:** ARPP (IP) growth driven by richer specialty mix, including **oncology strength** and **CONGO-T share up 80 bps**, alongside exit from low-yield schemes. * **Payor Mix Accretion:** Cash and insurance payors now represent **81% of mix**, a **280 bps improvement**, enhancing revenue quality and margin profile. * **Strategic Volume-Rate Trade-off:** Deliberate reduction in cluster scheme volumes (**1,500–1,600 fewer patients/quarter**) in Karnataka & Maharashtra due to **75% occupancy constraints**, boosting ARPP. * **External Pricing Tailwinds:** **CGHS price revisions** effective October, first in over a decade, uplift rates for **2,000+ procedures**, benefiting ESI, ECHS, and PSU billing. ## D. Medical Value Travel (MVT) * **MVT Momentum Accelerating:** National MVT volumes grew strongly QoQ and YoY, led by **Kerala’s 67% QoQ surge**, fueled by patients from Maldives, Middle East, and North Africa. * **Geographic Expansion:** Strategic focus expanding MVT reach into **pan-India and African markets**, with growing footfall from Oman and African belt. --- # 3. Cluster & Geography Mix ## A. Key Figures * **Kerala Revenue:** **₹620 Cr** (Q2 FY26) (+24% vs Q4 FY25) * **Kerala Patient Volume:** **+17% QoQ** (Inpatient +13%, Outpatient +17%) * **MVT Growth:** **+49%** in Kerala * **Whitefield Growth:** **~27%** in Karnataka * **Andhra & Telangana Volume Growth:** **+16% QoQ** (Inpatient & Outpatient) * **Nagercoil EBITDA Margin:** **>20%** within one year ## B. Kerala Performance * **Record Revenue & Volume Surge:** Kerala delivered highest-ever quarterly revenue and strong patient volume growth, re-established as a core growth engine with scale and operational excellence. * **Margin Expansion via Brownfield Leverage:** Margins rose across Medcity (>30%) and Kannur (>20%) due to brownfield expansions and cost optimization, despite prior leadership and seasonal headwinds. * **High-Acuity & MVT Momentum:** Growth broad-based beyond Medcity, led by robotic surgeries (>80/month) and a 49% surge in Medical Value Travel, supported by leadership stabilization and brand integration. ## C. Karnataka & Maharashtra * **Whitefield Outperforms with Oncology Tailwinds:** Whitefield posted robust ~27% growth, with oncology contributing 17% of Karnataka’s revenue, while Aster RV remains strong and CMI lags with single-digit growth. * **Hyderabad Turnaround Underway:** Previously underperforming units showed mid-double-digit growth in final month of Q2, with Women & Child greenfield poised to benefit from CARE’s network post-merger. ## D. Andhra & Telangana * **Stake Build & Strategic Review:** Aster increased ownership in Ramesh Hospitals to over 70%, triggering strategic cluster reviews and market studies, though no concrete changes confirmed yet. * **Margin Improvement Pathway:** Despite being low-margin (low double digits) and facing competition, the cluster shows turnaround signs with volume growth and physician investments driving performance gains. ## E. Tier 2 Expansion * **Tier 2 Scalability Validated by Nagercoil:** Nagercoil achieved EBITDA profitability in 3 months and >20% margins within a year, proving the dual-market strategy’s potential in regional cities. * **Balanced Geographic Strategy:** Company maintains flexible expansion approach across Tier 1 and Tier 2 markets, prioritizing execution speed, profitability, and long-term catchment growth without rigid allocation. --- # 4. Capacity & Bed Expansion ## A. Key Figures * **Occupancy Rate:** **64%** Q2 FY26 (from 59% Q1) · **Kerala: 69%**, **K&M: 62%**, **A&T: 55%** * **Total Beds:** **5,199** as of Sep-30, 2025 · **+200** added in past year * **Planned Bed Additions:** **>2,300** future beds · **>7,800** total capacity target ## B. Occupancy & Performance Trends * **Broad-Based Recovery:** Occupancy improved across all clusters, with **Kerala at record levels** and **K&M showing strongest rebound**, while A&T recovers from seasonal lows. * **Strong Operating Leverage:** Existing clusters delivering double-digit growth, minimizing margin pressure despite ongoing expansions. ## C. Expansion Strategy & Execution * **Accelerated Greenfield Rollout:** Three new hospitals targeted for launch by **FY27**, with **Nagercoil expansion moved forward to FY27** from FY28 on faster-than-expected demand. * **Tier-2 Focus for Scale:** Over **75% of new beds** (~1,300 of 1,700) planned for non-Metro markets to capture underserved demand and build long-term **higher ROCE** platforms. * **Proven Ramp-Up Model:** New facilities reaching **25% profitability in 3–4 quarters**, validating scalable operating model amid aggressive capacity build. ## D. Clinical Infrastructure Investment * **Targeted Tech Upgrades:** Deployed **LINAC, 2 Cath labs, 2 OCTs, 2 MRIs, and robotics** in high-potential micro-markets to boost service complexity and attract referrals. * **Enhanced Capabilities at Turnarounds:** Perinthalmanna now stable, with **linear accelerator and robotics** ordered to elevate clinical offerings and revenue mix. --- # 5. Specialty & Service Mix ## A. Key Figures * **Oncology Revenue Growth:** **26%** YoY (+200 bps mix gain to **11%** of total) * CONGO-T Share: Increased 80 bps to 58.5% * **MRR from New Clinicians:** **₹20 Cr** monthly run rate * Aster Labs EBITDA Margin: **17.8%** (from 11.0% in Q2 FY25) · **ROCE: 23%** in Q2 FY26 * **External Diagnostics Growth:** **31%** YoY · **Mature Unit Growth:** **15%** top-line ## B. Oncology Growth * **Strategic Expansion:** Oncology’s rising contribution reflects success in delivering **complex, high-value care**, with infrastructure build-out planned in Tier-2 regions via **5–7 LINAC systems** and robotic program scaling. * **Revenue Quality:** Over **40% of MedOnc revenue** derived from high-cost **immunotherapy and targeted therapies**, driving elevated ARPP (IP) despite margin pressure from material intensity. * **Growth Engine:** Whitefield hospital remains a key growth driver, with strong performance in **oncology, neuro, and cardiac services** boosting ARPOB and overall revenue. ## C. CONGO-T & Clinical Excellence * **Quality Shift:** Structured onboarding of **over 100 clinicians** has accelerated shift toward higher-acuity care, lifting CONGO-T share and reinforcing clinical leadership. * **Tertiary Care Positioning:** Facility functions as a **tertiary care hub** with advanced offerings in **Medical and Surgical Oncology**, supported by recruitment of **top-tier clinicians**. ## D. Robotic & Complex Care * **Clinical Innovation:** Recognized with **'Technology Transformation Initiative of the Year'** at FICCI Heal 2025 for **Walk-in FAPI PET/CT Imaging** at Aster Whitefield. * **Milestone Procedures:** Achieved multiple firsts, including **robotic-assisted CABG in Andhra Pradesh**, **TAVI with real-time CT integration**, and **awake beating-heart CABG on a high-risk patient**, underscoring technical leadership. ## E. Diagnostics Turnaround * **Operational Recovery:** Aster Labs delivered a sharp turnaround, with EBITDA margin expansion to **8%** driven by **31% external revenue growth** and cost efficiencies. * **Segmented Growth:** **60% of operations** in mature units growing at **15%**, while **25–27% from turnaround units**—notably **Hyderabad assets**—now contributing meaningfully to EBITDA. --- # 6. Risks & Healthcare Factors ## A. Key Figures * **Renewable Capacity:** **13 MW** commissioned (3 hospitals) · **21 MW** expected (7 hospitals) H2 FY26/FY27 * **Specialty Volume Trend:** **12% YoY degrowth** overall · **26% decline** in Karnataka ## B. GST Impact * **Net Neutral Margin Impact:** GST cuts on diagnostics and medicines reduce IP service revenue but are offset by **CGHS price increases**, resulting in stable to positive EBITDA. * **Structural Tailwind:** Lower GST on consumables enhances affordability and cost efficiency, favoring organized players like Aster. * **Operational Synergy Focus:** QCIL’s 10-point synergy wheel drives continuous efficiency gains beyond merger integration. ## C. Seasonal Demand * **Demand Resilience:** Hospital sector supported by strong domestic fundamentals, rising insurance, and growth in specialty/acute care demand. * **Base Effect Distortion:** Moderate Karnataka growth reflects tough YoY comparison due to **exceptionally high vector-borne disease volumes in FY25 Q2**. ## D. Material Cost Pressure * **Cost-Saving Runway:** Renewable energy rollout to deliver ongoing power cost reductions, with near-term expansion to 7 additional hospitals. --- # 7. Guidance & Outlook ## A. Key Figures * **H1 FY26 Capex:** **₹302 Cr** (nearly 50% for expansion) * **Post-Merger Scale:** **38 hospitals** across 27 cities · **10,360+ beds** * **ARPP (IP) Growth:** **7–8% p.a.** expected over next 2–3 years ## B. Margin Target * **Targeted Margin Range:** Merged entity guided to **24–25% EBITDA margins**, supported by **ARPP leverage** and merger synergies despite cost pressures. * **No Long-Term Guidance:** Management declined to provide specific 3–5 year EBITDA margin targets due to regulatory and sectoral uncertainties. * **Margin Expansion Drivers:** Synergies from **clinical collaboration, procurement optimization, and network rationalization** expected to enable margin resilience and growth across units. ## C. Capex Plan * **Strategic Capex Deployment:** Investments focused on **expansion, digital transformation, and clinical talent**, with H1 spend reflecting strong commitment to future-ready scaling. * **Greenfield Progress:** **Sarjapur** project to launch by end-H2 FY27, capex peaking mid-FY27; **Hyderabad** women & children’s hospital advancing. ## D. Merger Timeline * **Advanced Regulatory Clearance:** Merger with QCIL cleared by CCI, BSE/NSE (no-objection), and shareholders; now proceeding to **NCLT approval** and final sanction. * **Strategic Share Swap Completed:** Aster holds **5% in QCIL**; QCIL shareholders received **6% preferential stake in Aster**, now listed. * **Scaled National Footprint:** Combined entity to become one of India’s largest providers, operating **38 hospitals and over 10,360 beds**, enhancing scale and efficiency. ## E. Growth Projections * **Sustainable Growth Trajectory:** Confidence in long-term momentum underpinned by **institutionalized initiatives, footprint expansion, and integration roadmap**. * **ARPP Normalization Expected:** IP ARPP to stabilize with **low-to-mid single-digit growth** over next 2–3 years as Whitefield ramps mature.